FDA rejects Summit Therapeutics' lung cancer drug ivonescimab
Statements (8)
- Bearish
Summit Therapeutics shares dropped after the FDA declined to approve its lung cancer drug ivonescimab.
- Bearish
Summit Therapeutics stock crashed after the FDA rejected its lung cancer drug ivonescimab.
- Bearish
Astra Zeneca's partner Summit Therapeutics received a cold call from the FDA regarding market approval for cancer drug ivonescimab.
- Bearish
The FDA declined to approve a cancer drug for Summit Therapeutics
- Bearish
FDA did not approve Summit Therapeutics' China-developed lung cancer drug ivonescimab due to lack of statistically significant survival benefit.
- Bearish
FDA rejects ivonescimab treatment for lung cancer developed by Summit Therapeutics
- Bearish
FDA rejected ivonescimab, a lung cancer treatment from Summit Therapeutics and Akeso
- Neutral
FDA issued a Complete Response Letter regarding the BLA for ivonescimab in combination with platinum-containing chemotherapy for Summit Therapeutics